• Vascular endothelial growth factor and not cyclooxygenase 2 promotes endothelial cell viability in the pancreatic tumor microenvironment.

      Toomey, Desmond P; Manahan, Ellen; McKeown, Ciara; Rogers, Annamarie; McMillan, Helen; Geary, Michael; Conlon, Kevin C; Murphy, Joseph F; Professorial Surgical Unit, University of Dublin, Trinity College, Dublin, Ireland. (Pancreas, 2010-07)
      Cyclooxygenase 2 (COX-2) and vascular endothelial growth factor (VEGF), often coexpressed in cancer, are associated with poor prognosis. However, results from pancreatic cancer trials of their inhibitors were disappointing. This study delineated the role of COX-2 and nonsteroidal anti-inflammatory drugs in angiogenesis and VEGF regulation.